GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » EV-to-EBIT

CTNM (Contineum Therapeutics) EV-to-EBIT : -7.02 (As of Oct. 31, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Contineum Therapeutics's Enterprise Value is $222.84 Mil. Contineum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-31.73 Mil. Therefore, Contineum Therapeutics's EV-to-EBIT for today is -7.02.

The historical rank and industry rank for Contineum Therapeutics's EV-to-EBIT or its related term are showing as below:

CTNM' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.02   Med: 17.15   Max: 22.89
Current: -7.02

During the past 3 years, the highest EV-to-EBIT of Contineum Therapeutics was 22.89. The lowest was -7.02. And the median was 17.15.

CTNM's EV-to-EBIT is ranked worse than
100% of 419 companies
in the Biotechnology industry
Industry Median: 10.01 vs CTNM: -7.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Contineum Therapeutics's Enterprise Value for the quarter that ended in Jun. 2024 was $234.93 Mil. Contineum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-31.73 Mil. Contineum Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -13.50%.


Contineum Therapeutics EV-to-EBIT Historical Data

The historical data trend for Contineum Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics EV-to-EBIT Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only - - - - -7.41

Competitive Comparison of Contineum Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Contineum Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's EV-to-EBIT falls into.



Contineum Therapeutics EV-to-EBIT Calculation

Contineum Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=222.841/-31.725
=-7.02

Contineum Therapeutics's current Enterprise Value is $222.84 Mil.
Contineum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Contineum Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-31.725/234.931313
=-13.50 %

Contineum Therapeutics's Enterprise Value for the quarter that ended in Jun. 2024 was $234.93 Mil.
Contineum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.